The mature, hypusine-containing form of eukaryotic translation initiation factor 5A (EIF5A) in normal ovaries and in ovarian cancer: Anatomical evidence for a potential biomarker.

被引：0
|
作者：
Hanauske-Abel, HM
Cracchiolo, BM
Park, MH
Wolff, EC
Clement, PMJ
Heller, DS
机构：
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA
[2] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA
来源：
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION | 2004年 / 11卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
975
引用
收藏
页码：404A / 404A
页数：1
相关论文
共 44 条
  • [41] Inhibiting eukaryotic initiation factor 5A (eIF5A) hypusination attenuated activation of the SIK2 (salt-inducible kinase 2)-p4E-BP1 pathway involved in ovarian cancer cell proliferation and migration
    Lee, Grace Kelly
    Kim, Hae-Yeong
    Park, Jong Hwan
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (07) : 5807 - 5816
  • [42] Specific and sensitive GC-MS analysis of hypusine, Nε-(4-amino-2-hydroxybutyl)lysine, a biomarker of hypusinated eukaryotic initiation factor eIF5A, and its application to the bi-ethnic ASOS study
    Baskal, Svetlana
    Kaiser, Annette
    Mels, Catharina
    Kruger, Ruan
    Tsikas, Dimitrios
    AMINO ACIDS, 2022, 54 (07) : 1083 - 1099
  • [43] Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study
    Bexon, Alice S.
    Craig, Michael
    Siegel, David S.
    Bensinger, William
    Novitzky, Nicolas
    McDonald, Andrew
    Gutierrez, Martin
    Libby, Edward N.
    van Rhee, Frits
    Heidel, Jeremy
    Thompson, John
    Barranco, Charles
    Taylor, Catherine A.
    Donovan, Kathleen A.
    Moon-Tasson, Laurie L.
    Browne, Leslie J.
    Kurman, Michael R.
    Lust, John A.
    Dondero, Richard
    BLOOD, 2014, 124 (21)
  • [44] Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies
    Craig, Michael
    Bensinger, William
    Siegel, David Samuel DiCapua
    Van Rhee, Frits
    Novitzky, Nicolas
    Mcdonald, Andrew
    Gutierrez, Martin
    Libby, Edward N.
    Thompson, John
    Belton, Alice Susannah
    Barranco, Charles
    Taylor, Catherine
    Dondero, Richard
    Browne, Leslie J.
    Kurman, Michael R.
    Lust, John Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345